Action ONCOLOGY VENTURE A/S
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Oncology Venture A/S Nasdaq Stockholm

Actions

Cours en clôture Nasdaq Stockholm
Autres places de cotation
- SEK - Graphique intraday de Oncology Venture A/S
24/05 Allarity Therapeutics, Inc. conclut son essai clinique de phase 2 CI
02/05 Wall Street s'apprête à ouvrir en hausse jeudi après la décision de la Réserve fédérale de maintenir ses taux inchangés et après que les demandes d'allocations chômage aient été inférieures aux prévisions MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
Wall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than Expected
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
Top Premarket Gainers
Top Premarket Gainers
Allarity Therapeutics to Implement 1-for-20 Reverse Stock Split
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
Allarity Therapeutics : Material Agreement - Form 8-K
Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ALLR
  4. Action
  5. Actualités Oncology Venture A/S
  6. Autres langues